Company & Capital insights.
Company analysis, IPO landscape, and M&A trends
HKEX Chapter 18A: How Pre-Revenue China Biotechs IPO in Hong Kong (2026)
How pre-revenue China biotechs list in Hong Kong under HKEX Chapter 18A: the eligibility bar (HK$1.5B market cap, a Core Product through Phase 1, a sophisticated investor, the "-B" marker), the post-2024 recovery (14 new 18A listings in 2025), 18A vs Chapter 18C vs the STAR Market, lock-ups, and how a pending listing reshapes leverage in an out-licensing or M&A negotiation.
Who Funds China Biotech: The Cross-Border Investor & VC Map (2026)
A dealmaker’s map of who actually funds China biotech in 2026 — the USD vs RMB two-pool fund structure post-BIOSECURE, license-out as a financing substitute, VCs moving upstream into labs, and how a Western strategic or fund co-invests or builds a NewCo alongside Qiming, OrbiMed, LAV, Hillhouse and 5Y.
AI Drug Discovery Companies: The 2026 Power List
The leading AI drug discovery companies in 2026 ranked by capital and clinical validation — Isomorphic Labs, Xaira, Recursion, Insilico, Generate, Iambic, XtalPi and more — with a dealmaker’s read on who is real.
Biotech Investment Banking: The Complete Guide for 2026
Complete guide to biotech investment banking: top life science IB firms, deal types (M&A, IPO, licensing), valuation methods, and how to choose the right advisor for your transaction.
Biotech Venture Capital 2026: Definitive Investor Guide
$38B deployed in 2025. Top VC firms, investment stages, therapeutic area preferences, geographic trends, and the NewCo/platform creation trend reshaping biotech funding.
BeiGene: From China Biotech to Global Pharma Powerhouse
$3.8B revenue in 2024, BRUKINSA surpassing Imbruvica, and a 50+ asset pipeline. How BeiGene became China's most successful global biotech.
Biotech IPO & Funding Landscape 2026: The Window Reopens
The biotech IPO market surged back to life in late 2025. Track the biggest offerings, venture trends, and what makes a successful biotech IPO.
Biotech M&A 2026: Navigating the $200B Patent Cliff
A technical analysis of valuation multiples and integration savings in the consolidation wave.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.